XCNQ
DOSE
Market cap11mUSD
Jul 09, Last price
0.12CAD
1D
4.35%
1Q
14.29%
IPO
-85.00%
Name
Rapid Dose Therapeutics Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Rapid Dose Therapeutics Corp., a life sciences enterprise based in Burlington, Canada, specializes in cutting-edge drug delivery systems aimed at enhancing health and well-being for individuals across Canada. Their core offering is the QuickStrip/PharmaStrip, an innovative oral, fast-dissolving film designed to swiftly introduce active compounds—such as pharmaceuticals, emulsified oils, and over-the-counter remedies—directly into the bloodstream. The product line includes targeted solutions like QuickStrip energy, infused with caffeine; QuickStrip B12, providing vitamin B12; and QuickStrip sleep, which delivers melatonin. Furthermore, the company provides bespoke services encompassing product innovation, manufacturing, and strategic consultation to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing sectors. Rapid Dose Therapeutics also maintains a significant research partnership with McMaster University, jointly developing advanced biopolymer compositions for optimized thin-film drug delivery and pioneering an orally administered COVID-19 vaccine candidate.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑02 | 2025‑02 | 2024‑02 | 2023‑02 | 2022‑02 | 2021‑02 | 2020‑02 | 2019‑02 | 2017‑09 | 2016‑09 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||